Early Electrocardiographic Signs of Drug‐Induced Torsades de Pointes

Background: The aim of the present analysis was to identify early changes in the surface ECG predicting development of torsades de pointes (TdP) during treatment with almokalant, a Class III antiarrhythmic compound.

[1]  P Maison-Blanche,et al.  Time- and rate-dependent alterations of the QT interval precede the onset of torsade de pointes in patients with acquired QT prolongation. , 1997, Journal of the American College of Cardiology.

[2]  J. Papp,et al.  Differential Electrophysiologic Effects of Chronically Administered Amiodarone on Canine Purkinje Fibers versus Ventricular Muscle , 1996, Journal of cardiovascular pharmacology and therapeutics.

[3]  B. Darpö,et al.  Almokalant—A Selective Class III Antiarrhythmic Compound , 1996 .

[4]  S. Hohnloser,et al.  Amiodarone Therapy After Previous Sotalol-induced Torsade de Pointes: Analysis of QT Dispersion to Predict Proarrhythmia , 1996, Journal of cardiovascular pharmacology and therapeutics.

[5]  P. Insulander,et al.  Selective Ik blocker almokalant exhibits class III--specific effects on the repolarization and refractoriness of the human heart: a study of healthy volunteers using right ventricular monophasic action potential recordings. , 1995, Journal of cardiovascular pharmacology.

[6]  P. Coumel,et al.  Spontaneous sequences of onset of torsade de pointes in patients with acquired prolonged repolarization: quantitative analysis of Holter recordings. , 1995, Journal of the American College of Cardiology.

[7]  R. Bergstrand,et al.  Tolerance and Effects of Almokalant, a New Selective Ik Blocking Agent, on Ventricular Repolarization and on Sino‐Atrial and Atrioventricular Nodal Function in the Heart: A Study in Healthy, Male Volunteers Utilizing Transesophageal Atrial Stimulation , 1995, Journal of cardiovascular pharmacology.

[8]  Craig D. Miller,et al.  Management of Patients With Intramural Hematoma of the Thoracic Aorta , 1993, Circulation.

[9]  H. Crijns,et al.  Torsades de pointes with Almokalant, a new class III antiarrhythmic drug. , 1993, American heart journal.

[10]  J E Axenborg,et al.  A PC-based on-line system for physiological in vivo and in vitro experiments. , 1993, Computer methods and programs in biomedicine.

[11]  D. Wyse,et al.  Precordial QT Interval Dispersion as a Marker of Torsade de Pointes: Disparate Effects of Class Ta Antiarrhythmic Drugs and Amiodarone , 1992, Circulation.

[12]  H Just,et al.  Intraindividual Reproducibility of Heart Rate Variability , 1992, Pacing and clinical electrophysiology : PACE.

[13]  J. Bigger,et al.  Clinical types of proarrhythmic response to antiarrhythmic drugs. , 1987, The American journal of cardiology.

[14]  R. Goldstein,et al.  PROARRHYTHMIC EFFECTS OF ANTIARRHYTHMIC DRUGS* , 1984, Annals of the New York Academy of Sciences.

[15]  J. Barlow,et al.  Sotalol, hypokalaemia, syncope, and torsade de pointes. , 1984, British heart journal.

[16]  G. Kay,et al.  Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. , 1983, Journal of the American College of Cardiology.

[17]  P. Coumel,et al.  [Ventricular fibrillation and twisted peaks]. , 1969, La Presse medicale.

[18]  P. Coumel,et al.  Fibrillation ventriculaire et torsades de pointes. , 1969 .